Financial Results for the First Half of Fiscal Year
Ending March 31, 2020 (FY2019)

from the beginning

Adapting to a New Healthcare Era: Disease-oriented Approachs

• Key Initiatives towards Sustainable Growth <Leverage Group’s Comprehensive Strength>

• Paradigm Shift in Healthcare

• What is “Disease‐oriented Approach” for Terumo?

• [Oncology] Deliver Diversified and Cross-divisional Solutions

• [Oncology] Unique Solutions to Maximize Therapy Outcomes

• [Oncology] Already Being a Main Player for Supportive Care in JP

• [Oncology] Interventional Oncology: Utilize Strong Delivering Technologies

• [Diabetes] Add Advanced Products to Create Total Solutions

• [Chronic heart failure] CHF is An Urgent Social Challenge

• [Chronic heart failure] Unique Portfolio Comprehensively Covers Heart Disease

• [Foot care] Broad Portfolio Covering from Prevention of Primary Disease to Progression Prevention

• Create Optimal Solutions Through Adding New Capabilities

• Conclusion

IR Contact

Financial Results for the First Half of Fiscal Year Ending March 31, 2020 (FY2019)

• Highest-ever 1H Revenue and Profit

• Adjusted Operating Profit Variance Analysis

• Revenue by Region

• Revenue by Business Segment

• Cardiac and Vascular: Positive Growth in All Businesses. Significant Increase in Revenue and Profit

• General Hospital: Revenue and Profit in Line with the Guidance

• Blood Management: Returned to Positive Growth in Revenue. Profitability Recovered as Planned

• Factors for Higher Profit Than 1H Guidance and Risks in 2H

• Major Topics in FY19 Q2

• New Products Pipeline in FY19

Reference

• 1H FY19 Revenue and Growth by Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit : Adjustments

• CAPEX and R&D Expenses

• Cash Flows

• Foreign Exchange Sensitivity

• The Status of Convertible Bonds

IR Contact